Assenagon Asset Management S.A. Acquires 492,800 Shares of DexCom, Inc. $DXCM

Assenagon Asset Management S.A. lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 40.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,719,249 shares of the medical device company’s stock after purchasing an additional 492,800 shares during the quarter. Assenagon Asset Management S.A.’s holdings in DexCom were worth $107,969,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Trust Co. of Vermont lifted its position in shares of DexCom by 14.8% in the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after buying an additional 145 shares during the last quarter. CVA Family Office LLC raised its stake in shares of DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares in the last quarter. IFP Advisors Inc raised its stake in shares of DexCom by 24.7% in the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock valued at $61,000 after acquiring an additional 178 shares in the last quarter. Keel Point LLC lifted its holdings in DexCom by 3.1% in the 4th quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock worth $430,000 after purchasing an additional 193 shares during the last quarter. Finally, Integrated Wealth Concepts LLC lifted its holdings in DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after purchasing an additional 196 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other DexCom news, Director Mark G. Foletta sold 4,000 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $74.13, for a total value of $296,520.00. Following the sale, the director directly owned 52,852 shares in the company, valued at $3,917,918.76. This trade represents a 7.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the transaction, the insider owned 382,482 shares in the company, valued at approximately $27,538,704. The trade was a 6.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 46,694 shares of company stock valued at $3,343,977 in the last three months. 0.28% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have commented on DXCM shares. Bank of America lowered their price target on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Weiss Ratings restated a “hold (c-)” rating on shares of DexCom in a research note on Monday, June 1st. Deutsche Bank Aktiengesellschaft started coverage on shares of DexCom in a report on Tuesday. They set a “buy” rating and a $86.00 price objective for the company. TD Cowen reiterated a “buy” rating and issued a $95.00 target price (up from $75.00) on shares of DexCom in a research note on Wednesday, June 10th. Finally, Sanford C. Bernstein set a $77.00 target price on shares of DexCom in a report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $84.88.

DexCom Stock Performance

DXCM opened at $69.73 on Thursday. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The stock’s 50 day moving average price is $67.36 and its two-hundred day moving average price is $68.04. The firm has a market capitalization of $26.91 billion, a P/E ratio of 29.80, a price-to-earnings-growth ratio of 1.08 and a beta of 1.45. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same period in the previous year, the company earned $0.32 earnings per share. The company’s quarterly revenue was up 15.0% compared to the same quarter last year. On average, equities analysts forecast that DexCom, Inc. will post 2.58 earnings per share for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.